DISCLAIMER
The information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.compose your message
message sent
email sent successfully
Trusted Resources: News & Events
Latest announcements and gatherings
A multiple drug approach to preventing sickle cell crisis
Sickle cell disease is characterized by recurrent episodes of “sickle crisis,” also known as vaso-occlusive crisis, in which a patient’s red blood cells change shape, clump together and block the flow of blood in small vessels resulting in pain and organ damage.
In an editorial in the current issue of the New England Journal of Medicine, a Boston University School of Medicine (BUSM) researcher stresses the need for a multi-pronged approach to treating sickle-cell disease in order to prevent these harmful episodes.
+myBinderRelated Content
-
education & researchContrary to expectations: seasonal variation in sickle cell crisis – a nation wide data analysisBackground: Sickle cell crisis is a pain...
-
news & eventsPartnership to Ensure Supply of LentiGlobin, Potential Gene TherapyBluebird Bio extended a partnership with...
-
education & researchPrevention of acute sickle cell crisis: review of the NEJM reportA recent article in the New England Jour...
-
news & eventsNew Guidelines for Managing Sickle Cell Disease Presented at ACP Internal Medicine MeetingNew guidelines for therapeutic strategie...
-
videos & visualsAdvances in the Treatment of Sickle Cell Disease: L-Glutamine, Crizanlizumab & Gene Therapyhttps://www.youtube.com/watch?v=wkm4axJ3...
-
news & eventsDifferences in Brain Oxygen Supply May Explain Silent Strokes in SCD PatientsBrain oxygen supply is different in diff...
-
news & eventsMARAC Statement: Crizanlizumab (Adakveo)July 7, 2023 - SCDAA’s Medical and Res...
send a message
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.